|
Active substance |
Daratumumab |
|
Holder |
Janssen-Cilag NV |
|
Status |
Closed |
|
Indication |
Patients who have relapsed and refractory multiple myeloma (MM), who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or whose disease is double refractory to both a PI and an IMiD |
|
Public documents |
|
|
Last update |
01/03/2017 |
Darzalex®
Last updated on 13/09/2024